Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Novartis Keen to Ensure Stable Supply of Radioligand Therapies in Japan
May 26, 2025
-
ORGANIZATION FPMAJ Sets Out on New Lobbying Push with Astellas’ Yasukawa as New Chief
May 23, 2025
-
ORGANIZATION Takeda’s Miyabashira Elected as New JPMA President
May 23, 2025
-
BUSINESS Japan Pharma Market Grows 1% to Record 11.4 Trillion Yen in FY2024: IQVIA
May 23, 2025
-
BUSINESS MSD Chief Decries Japan’s Unpredictable Policy Flip, Frets Future Investment
May 22, 2025
-
BUSINESS Sanofi Japan Seeing Improved Customer Satisfaction with AI-Powered Sales Support Tool
May 21, 2025
-
REGULATORY Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
-
ORGANIZATION PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
May 19, 2025
-
BUSINESS Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO
May 16, 2025
-
REGULATORY Chuikyo Agrees to Vet Conditional Scheme for Regenerative Medicine as Elevidys Gets Approval
May 15, 2025
-
REGULATORY Eylea’s Price to Be Axed by 19.5%, Jardiance 12.1% in Market Expansion Rule
May 15, 2025
-
REGULATORY Wegovy, Leqvio, Phozevel Braced for Price Cuts after CEA
May 15, 2025
-
REGULATORY Chuikyo Plans Monthly Debates for CEA Reform in FY2026
May 15, 2025
-
REGULATORY Epkinly, Lunsumio to Face Price Cut of 2.7% under CEA Scheme
May 15, 2025
-
REGULATORY Japan’s Parliament Enacts Bill to Amend PMD Act
May 15, 2025
-
REGULATORY LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing
May 14, 2025
-
ACADEMIA Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
May 14, 2025
-
BUSINESS J&J Taps Chris Rieger to Lead Japan Pharma Business
May 13, 2025
-
REGULATORY MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
-
BUSINESS Takeda on Course to Stable Growth as Late-Stage Assets Near Market
May 9, 2025
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…